MilliporeSigma Announces Collaboration with Agilent Technologies to Fill Industry Gap in Process Analytical Technologies for Downstream Processing

MilliporeSigma today announced that the Life Science business has entered a collaboration with Agilent Technologies to advance Process Analytical Technologies (PAT).

14 Jun 2022 | Burlington, Alabama, United States of America
  • Collaboration will help enable real-time release and Bioprocessing 4.0
  • MilliporeSigma to offer integrated capabilities for downstream process monitoring and control
  • Online Process Analytical Technologies a critical tool towards implementing continuous manufacturing to realize Bioprocessing 4.0

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that the Life Science business has entered a collaboration with Agilent Technologies to advance Process Analytical Technologies (PAT). PAT, which is strongly encouraged by global regulatory authorities, is a key enabler for real-time release and Bioprocessing 4.0.

“The biopharmaceutical industry is on a rolling transformation to evolve and digitalize the next generation of bioprocessing to increase accessibility and lower the cost of biologics,” said Darren Verlenden, Head of BioProcessing, Life Science business sector of Merck KGaA, Darmstadt, Germany. “By combining our advanced bioprocess portfolio with Agilent’s leading analytical solutions, we will be able to offer integrated capabilities for enhanced downstream process monitoring and control, bringing us one step closer to making the facility of the future a reality.”

With this collaboration, the Life Science business sector of Merck KGaA, Darmstadt, Germany, and Agilent Technologies are filling an industry gap in downstream PAT. By combining the Life Science business’ bioprocess portfolio with Agilent Technologies’ advanced analytical products, the Life Science business extends real-time monitoring and automated process control of critical process parameters (CPPs) and critical quality attributes (CQAs) to downstream processing.

“Integrating analytical capabilities and intelligence into bioprocessing enables the Biopharma industry to accelerate biological drug development and manufacturing while supporting continuous manufacturing and real-time release,” said Stefan Schuette, Vice President and General Manager of Agilent´s Liquid Phase Separations Division. “This collaboration focuses on integrating Agilent’s new Online liquid chromatography (LC) solution with the Life Science business’ bioprocessing platforms and will support customers on their journey to develop and produce biological drugs faster, with greater confidence, and at lower cost.”

Downloads

For more information please contact Rachel Bloom-Baglin

Follow MilliporeSigma on Twitter @MilliporeSigma, on Facebook @MilliporeSigma and on LinkedIn.

All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.

About the Life Science business of Merck KGaA, Darmstadt, Germany

The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has more than 26,000 employees and 55 manufacturing and testing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and electronics.

Around 60,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2021, Merck KGaA, Darmstadt, Germany generated sales of € 19.7billion in 66 countries.

The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck KGaA, Darmstadt, Germany, visit www.emdgroup.com.

 

 

 

Related News

  1. Press Releases

    MilliporeSigma Opens US$ 65 Million CDMO Facility to Address Demand for Critical ...

    MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, has doubled its high-potent active pharmaceutical ingredients (HPAPI) production capacity with the expansion of ...

    2022/06/23